Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Introduction: Valued at more than $12 billion USD in 2019, the global market for facial aesthetics—including the aesthetic injectable, cosmeceutical, breast implant, and energy-based device markets in North America ($5.5 billion USD), Europe ($2.5 billion USD), the Asia Pacific ($2.8 billion USD), and Latin America ($1.4 billion USD)—will grow at a compound annual growth rate (CAGR) of approximately 7.7% from 2018 to 2023.
The global aesthetic market continues to grow at a robust pace, fueled by new product launches and the novel product indications, ongoing marketing efforts from major competitors, and an expanding patient pool increasingly consisting of nontraditional demographic groups. Accessibility to aesthetic treatments—supported by the rise in non-core physicians and places like medispas and beauty bars offering procedures—is also contributing to market expansion.
However, as aesthetic procedure volumes continue to increase at a rapid pace worldwide and as new patient populations, particularly the young in their late teens and early adulthood opt for these procedures, it has become evident that that greater oversight is needed in this space to prevent adverse events among patents and to prohibit malpractice. This has come in the form of major regulatory changes like the European MDR, as well as smaller-scale country-specific measures to control the types of practitioners and facilities administering treatments, ways that products and procedures are marketed to patients, and more stringent management of the products, treatments, and indications. This has prompted aesthetics competitors to respond accordingly with extensive physician training programs, heightened focus on clinical data, improvement in product traceability, and the creation of dedicated teams to track and react to increased regulatory oversight.
Nonetheless, there remains significant revenue potential in the global aesthetics market. Facial Injectables and energy-based device markets will be the fastest-growing segments due to increasing patient demand. Globally, the mature US market will remain the largest, while Asia Pacific market will expand rapidly due to the general underpenetration of aesthetic procedures in the region. Ultimately, growth in all segments across all regions will allow the global aesthetics market to expand at a swift pace in the next few years.